Last reviewed · How we verify
NCT03886571
U01-Biomarkers for Noninvasive and Early Detection of Pancreatic Cancer
trial in Pancreatic Cancer in 100 participants. Status unknown.
15 September 2023
Quick facts
| Lead sponsor | Hoag Memorial Hospital Presbyterian |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 100 |
| Start date | 15 September 2018 |
| Primary completion | 15 September 2023 |
| Estimated completion | 15 September 2024 |
| Sites | 1 location across United States |
Conditions studied
- Pancreatic Cancer — all drugs for Pancreatic Cancer →
Sponsor
Hoag Memorial Hospital Presbyterian
Who can join
18 and older, any sex, with Pancreatic Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is an observational, biospecimen collection protocol to develop a bank of pancreatic cancer tissue and normal tissue.
Publications & conference data
6 peer-reviewed publications reference this trial (live from Europe PMC):
-
Targeting miRNAs and Other Non-Coding RNAs as a Therapeutic Approach: An Update.
Bayraktar E, Bayraktar R, Oztatlici H, Lopez-Berestein G, et al · · 2023 · cited 51× · PMID 37104009 · DOI 10.3390/ncrna9020027 -
Cancer-Derived Extracellular Vesicle-Associated MicroRNAs in Intercellular Communication: One Cell's Trash Is Another Cell's Treasure.
Mills J, Capece M, Cocucci E, Tessari A, et al · · 2019 · cited 51× · PMID 31817101 · DOI 10.3390/ijms20246109 -
miRNAs in pancreatic cancer progression and metastasis.
Mok ETY, Chitty JL, Cox TR. · · 2024 · cited 42× · PMID 38240887 · DOI 10.1007/s10585-023-10256-0 -
Circulating microRNAs as Potential Biomarkers in Pancreatic Cancer-Advances and Challenges.
Seyhan AA. · · 2023 · cited 36× · PMID 37686149 · DOI 10.3390/ijms241713340 -
Current status and perspectives of genetic testing in gastrointestinal cancer (Review).
Matsuoka T, Yashiro M. · · 2024 · cited 4× · PMID 38058469 · DOI 10.3892/ol.2023.14155 -
Biomarkers for Early Detection of Pancreatic Cancer.
Bengtsson A, Andersson R, Linders J, Gulla A, et al · · 2025 · cited 3× · PMID 40612538 · DOI 10.1159/000546584
Verify or expand the search:
- PubMed search for NCT03886571
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Pancreatic Cancer
Currently open trials in the same condition.
- NCT07126158 — Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma · Phase 2 · recruiting
- NCT07353645 — KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer · Phase 1, PHASE2 · recruiting
- NCT07439757 — AI-Powered Precision Decision-Making for Pancreatic Diseases · recruiting
- NCT07409272 — A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherap · Phase 3 · recruiting
- NCT07236177 — B-GLUCANCER2 : A Pilot Study Evaluating a New Method for Cancer Detection by Measuring the Activity of Different Glycosi · EARLY_PHASE1 · recruiting
Other Hoag Memorial Hospital Presbyterian trials
Trials by the same sponsor.
- NCT06736054 — A Phase I Trial of 61Cu-NODAGA-PSMA for Patients with Prostate Cancer · Phase 1 · recruiting
- NCT05880394 — Study of Dotatate Imaging in Breast Cancer · Phase 2 · unknown
- NCT04814615 — A Diagnostic Study of CD38-Targeted ImmunoPET of Myeloma · Phase 2 · unknown
- NCT04700332 — PyL in Patients With High Risk and Biochemically Recurrent Prostate Cancer · Phase 2 · recruiting
- NCT04883814 — 18F-fluoroestradiol (FES) PET/CT for Breast Cancer · Phase 2 · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03886571 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hoag Memorial Hospital Presbyterian
- Last refreshed: 1 March 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03886571.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing